We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Bio Nano Consulting Signs Agreement with The School of Pharmacy, University of London

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Bio Nano Consulting Signs Agreement with The School of Pharmacy, University of London"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
Bio Nano Consulting (BNC), specialists in bio and nanotechnology partnerships between the academic and industrial sectors, announces the signing of a service level agreement (SLA) with The School of Pharmacy, University of London.

This latest SLA enables BNC to offer an expanded service offering to life science and pharma companies as it provides access to an increased pool of academic experts skilled in the fields of pharmaceutics, pharmacology and drug discovery.

At the same time, BNC has already utilized the new arrangement to secure a contract with an undisclosed US-based biotechnology company. Under the terms of the agreement, BNC will manage a specific project, carried out by scientists at the School of Pharmacy, to formulate a phase I cancer drug with the goal of making the treatment orally available, rather than delivered intravenously.

The four month proof of concept project is intended to demonstrate dissolution and oral availability and, once successful, will progress to a second project stage with School scientists working closely with the biotechnology company to take the formulation through to late-stage development. Undisclosed licensing and milestone terms have been agreed between the School and the client, subject to formulation success.

The School’s strong scientific resources are entirely complementary to BNC’s existing nanotechnology and bioengineering services, provided through the London Centre for Nanotechnology at University College London (UCL) and Imperial College London respectively. In particular at the School, Professor Ijeoma Uchegbu is one of the leading experts in the combined areas of nanoscience, nanotechnology, drug delivery, polymer chemistry, molecular self assembly and gene delivery.

Prof. Uchegbu has developed a suite of nanotechnology formulation IP, which has demonstrated proof of concept by delivering other gut labile drugs and poorly water soluble drugs, both of which are extremely difficult to deliver via this route.

The School’s research primarily focuses on both advancing and understanding medicines and health care whilst also creating new medicines for the healthcare sector. It is organized into four divisions comprising Drug Discovery, Neurosciences, Formulation Sciences and Medicines Use and Health. In the 2008 Research Assessment Exercise for British universities, 90 per cent of the School’s research activity was deemed internationally significant with 25 per cent considered world-leading.